Brief: Egetis Therapeutics FY Adjusted EPS SEK -1.1
26/02/2025 06:00
Feb 26 (Reuters) - Egetis Therapeutics FY net income SEK -343.6 million. FY revenue SEK 46.1 million vs. IBES estimate SEK 55.6 million
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1